Elevidys (delandistrogene moxeparvovec) can now be used to treat both ambulatory and non-ambulatory boys aged four and above with DMD, a major expansion on its earlier accelerated approval with a ...

Exon-skipping therapies could, however, become superseded by a new generation of gene therapies for DMD, led by Sarepta’s Elevidys (delandistrogene moxeparvovec), which was cleared by the FDA ...

However, despite finding such benefits with prophylactic,… Two years after receiving the gene therapy Elevidys (delandistrogene moxeparvovec-rokl), motor function continues to improve in boys with ...

As of 3:13:11 PM EDT. Market Open. Loading Chart for SRPT ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.